Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 143,206 shares, a decrease of 97.1% from the April 15th total of 5,006,970 shares. Approximately 6.0% of the company’s stock are short sold. Based on an average daily volume of 2,702,976 shares, the short-interest ratio is currently 0.1 days.

Virax Biolabs Group Trading Up 4.6%

NASDAQ:VRAX traded up $0.01 during trading hours on Tuesday, reaching $0.16. 1,006,625 shares of the stock were exchanged, compared to its average volume of 9,605,580. The firm has a 50 day simple moving average of $0.17 and a 200-day simple moving average of $0.31. Virax Biolabs Group has a 52 week low of $0.10 and a 52 week high of $1.20.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Zacks Research raised Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.00.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.